×

Global Markets 2011 - Special Report

Mike Huckman

More

  • One of the many things I think is great about Twitter is the direct contact it gives me with a handful of biopharma reporters who are using it.

  • Carl Icahn, reputed to be a late-riser, woke up to good news and bad news today.

  • Shares of Teva Pharmaceutical Industries are once again trading at an historic high. But they might not be there today if it weren’t for a tragedy.

  • Teva and Pfizer

    The 800-pound gorilla of one industry has beaten the 800-pound gorilla of another. Teva CEO Shlomo Yanai took on Pfizer CEO Jeff Kindler and won.

  • Axiron

    I can hear the commercial now. “Underarm protection that literally makes you feel more like a man.”

  • FDA

    Of course, I'm off the day all heck breaks loose on the beat and stocks are making big moves all over the place.

  • Tomorrow is the day the agency is scheduled to announce if the first once-a-week diabetes treatment, a rejiggered version of the now twice-a-day Byetta, can come to market.

  • trader

    On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.

  • gsk_perfume_ad.jpg

    It's not quite the same as waiting for new, entertaining commercials during the Super Bowl, but there was a noteworthy premiere during last night's Academy Awards.

  • This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."